Rare Neurological Disease Treatment Market Research Report 2027

[Research Report] The rare neurological disease treatment market is expected to reach US$13,830.96 Mn in 2027 from US$ 7,300.12Mn in 2019. The market is estimated to grow with a CAGR of 8.5% from 2020-2027.

Neurological diseases having less diagnostics and treatment options affecting small number of population is termed as rare neurological diseases. These diseases target the nervous system, which include the brain, spinal cord, and all the nerves that run throughout the human body. Amyotrophic lateral sclerosis (ALS), Duchenne muscular dystrophy, Huntington's disease are few examples of rare neurological conditions. The global rare neurological disease treatment market is driven by factors such as rising prevalence of rare neurological diseases and favorable pipeline drugs and robust research activities for the treatment of rare neurological diseases. However, high treatment cost for rare neurological diseases are likely to show negative impact on market growth during the forecast period.

Lucrative Regional Rare Neurological Disease Treatment Markets

Get more information on this report : Request Free Sample PDF

Market Insights

Rising Prevalence of Rare Neurological Diseases

In the world of medicine, rare neurological diseases represent significant burden on health systems in terms of disease diagnosis, treatment, and management. Some of the majorly observed rare neurological diseases comprises narcolepsy, amyotrophic lateral sclerosis, Alzheimer’s disease, multiple sclerosis, spinal muscular atrophy (SMA), Duchenne muscular dystrophy, and others. According to a data published by National Institutes of Neurological Disorders and Stroke in 2019, 7,000 rare neurological diseases have been registered in the US. Additionally, according to the same study, these conditions are responsible for significant number of morbidity and mortality.

Deprivation of sleep, psychological stress, an inherited genetic fault, sudden change in sleep patterns, and aging are the main factors that accelerate the prevalence of rare neurological diseases. Considering these factors, the elderly population is highly vulnerable for neurological conditions. For instance, as per the study published in Annals of Neurology in 2017, around 100 million US populations was affected by the rare neurological disease in 2011. Moreover, these diseases are responsible to increase the morbidity and disability, which affects the economic condition of the country. Neurological sleep related disorders are expected to increase in coming years owing to the increasing ageing population across the world. According to the data published by National Institute of Health (NIH) in 2019, approximately 40 million Americans suffer from neurological diseases in the US, whereas additional 20 million people experience occasional sleeping problems.

Indication Insights

Based on indication, the rare neurological disease treatment market is segmented into narcolepsy, amyotrophic lateral sclerosis, Alzheimer’s disease, multiple sclerosis, spinal muscular atrophy (SMA), Duchene muscular dystrophy, and other indications. The Alzheimer’s disease segment held the largest share of the market in 2019 and is estimated to register the highest CAGR in the market during the forecast period. The disease accounts for nearly 60% to 80% of all dementia cases and is widely seen among the aging population.

Global Rare Neurological Disease Treatment Market, by Indication – 2018 & 2027

Get more information on this report : Request Free Sample PDF

Drug Type Insights

Based on drug type, the rare neurological disease treatment market is segmented into organic compounds, and biologics. The biologics segment held the largest share of the market in 2019 and is estimated to register the highest CAGR in the market during the forecast period.

Distribution Channel Insights

Based on distribution channel, the rare neurological disease treatment market is segmented into online pharmacies, hospital pharmacies, and retail pharmacies. The hospital pharmacies segment held the largest share of the market in 2019 however, retail pharmacies is estimated to register the highest CAGR in the market during the forecast period.

Mode of Administration Insights

Based on mode of administration, the rare neurological disease treatment market is segmented into oral and injectable. The oral segment held the largest share of the market in 2019 and is estimated to register the highest CAGR in the market during the forecast period

Strategic Insights

Product launches and FDA approvals strategy is commonly adopted by companies to expand their footprint worldwide and meet the growing demand. This strategy is most commonly adopted by the market players in order to expand its product portfolio.

The market players operating in the rare neurological disease treatment market adopt the strategy of collaborations to enlarge customer base across the world, which also permits the players to maintain their brand name globally.

Global Rare Neurological Disease Treatment Market– By Indication

• Narcolepsy
• Amyotrophic Lateral Sclerosis
• Alzheimer’s Disease
• Multiple Sclerosis
• Spinal Muscular Atrophy (SMA)
• Duchenne Muscular Dystrophy
• Other Indications

Global Rare Neurological Disease Treatment Market– By Drug Type

• Organic Compounds
• Biologics

Global

Rare Neurological Disease Treatment Market– By Distribution Channel

• Online Pharmacies
• Hospital Pharmacies
• Retail Pharmacies

Global Rare Neurological Disease Treatment Market – By Mode of Administration

• Oral
• Injectable

Rare Neurological Disease Treatment Market – By Geography

• North America
  • US
  • Canada
  • Mexico
• Europe
  • France
  • Germany
  • Italy
  • UK
  • Spain
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • South Korea
  • Japan
  • Australia
  • Rest of Asia Pacific
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East and Africa
• South America
  • Brazil
  • Argentina
  • Rest of South America

Company Profiles

• Allergan plc
• Bayer AG
• GlaxoSmithKline plc
• Johnson & Johnson Services Inc
• Merck & Co. Inc.
• Novartis AG
• Pfizer Inc.
• Sanofi
• Teva Pharmaceutical Industries Ltd
• Takeda Pharmaceutical